002800.KQ

Strong BuyUnloved QualityAI neutral

Sinsin Pharmaceutical Co., Ltd · Healthcare · South Korea · $51M cap · $96K/day traded

KRW 4,315 +0.1% · close 19 Oct · scored 20 Oct

Unloved Quality: Strong and cheap; the market has not turned yet.

96
StockRank
Get score and insider alerts
Quality
69
Value
86
Momentum
49

As of 20 Oct 2026, MoatMap's StockRank for Sinsin Pharmaceutical Co., Ltd (002800.KQ) is 96/100, ranked against 24,000+ stocks in 35 markets (Quality 69, Value 86, Momentum 49, each scored against its sector).

Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →

P/E (TTM)
7.0x
peers 16.2x
ROE
18.3%
peers -0.3%
D/E
0.5x
peers 0.3x
Dividend %
1.9%
trailing yield
AI CONVICTION THESIS

Sinsin Pharmaceutical is a small Korean maker of medicated patches and over-the-counter products that screens as cheap with reasonable quality. There is no recent company-specific news or filing that points to a catalyst, a durable competitive edge or a growth runway beyond its domestic consumer health niche.

ABOUT SINSIN PHARMACEUTICAL CO., LTD

Read

Sinsin Pharmaceutical Co., Ltd manufactures and sells pharmaceutical products in South Korea. It offers various medicinal products, such as plaster, aerosol, topical liquid, emollient, hygiene, and ointment products, as well as adhesive bandages, mosquito repellents, anti-perspirants, cooling...

FINANCIAL SUMMARY (KRW)

Year2022202320242025CAGRTTM
Revenue91.9B102.6B106.4B113.8B7.4%122.9B
EPS (KRW)291.00308.00322.00613.0028.2%612.11
Shares15.2M15.2M15.2M15.2M0.0%15.2M
Debt43.5B44.5B45.6B43.7B0.2%40.0B
Equity59.7B62.3B65.9B74.8B7.8%—
Op CF5.5B3.9B5.9B8.6B16.3%14.0B
Inv CF-1.1B-6.1B-5.6B-2.3B——
Fin CF-2.8B225.5M-208.4M-2.9B——
Loading 1Y...
PRICE (1Y) · KRW-8.4%
4,2104,3354,4604,5854,7102 Sep23 Sep19 Oct
SMA 50SMA 200

Price checkFinding a floorExperimental

No new 52-week low for 10 weeks, 11% above that low, but not back above a rising 50-day average.

SwingsBumpy

Swung more than 51% of stocks we rank over the past year (42% a year).

How this is worked out

StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.

The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.

What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.

Calm is not safe: a calm stock can still slide steadily.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
KRW 4,315
RSI (14)
43.7
52-Week Range-37.4% from high
Low KRW 3,900High KRW 6,893.25

SCORE BREAKDOWN

Quality
69
ROIC
17.6%87.3
ROE
18.3%86.3
GP/Assets
36.0%73.9
Op. Margin
12.0%67.6
FCF/Assets
5.1%68.3
Piotroski
893.7
Int. Cover
8.9x60.2
D/E Ratio
0.51x29.6
Current Ratio
1.07x13.0
Value
86
P/E (TTM)
7.0x94.9
EV/EBITDA
5.5x90.0
P/FCF
10.0x82.7
P/B
0.9x86.6
P/S
0.5x91.7
Div Yield
1.9%54.3
Momentum
49
52W High %
63%43.8
RS 6M
-20%42.4
SMA 50/200
0.88x26.4
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
169%89.8

FUNDAMENTALS

Market Cap
$51M
P/E (Forward)
—
Gross Margin
39.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 002800.KQ are excluded.

TickerCompanyMkt CapStockRankSignal
002800.KQSinsin Pharmaceutical Co., Ltd(you)$51M96Strong Buy
012790.KQSinil Pharmaceutical Co., Ltd.$52M99Strong Buy
072020.KQChoong Ang Vaccine Laboratory Co., Ltd.$63M93Strong Buy
001540.KQAhn-Gook Pharmaceutical Co., Ltd.$84M100Strong Buy
234080.KSJW Lifescience Corporation$126M97Strong Buy
023910.KQDaihan Pharmaceutical Co.,Ltd.$114M99Strong Buy
054670.KQDaehan Nupharm Co.,Ltd.$56M78Buy
106190.KQHigh Tech Pharm Co., Ltd.$78M82Strong Buy
016580.KSWhan In Pharm Co.,Ltd.$137M99Strong Buy
008490.KSSuheung Co., Ltd.$163M93Strong Buy

Peer medians: ROE -0.3% · P/E 16.2x · Gross margin 43.4%

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

Sinsin Pharmaceutical Co., Ltd (002800.KQ): Stock Score Summary

Sinsin Pharmaceutical Co., Ltd (002800.KQ) has a MoatMap StockRank of 96/100 based on Quality (69/100), Value (86/100), and Momentum (49/100) factor scores. The current signal is STRONG BUY. Sinsin Pharmaceutical is a small Korean maker of medicated patches and over-the-counter products that screens as cheap with reasonable quality. There is no recent company-specific news or filing that points to a catalyst, a durable competitive edge or a growth runway beyond its domestic consumer health niche.

Sinsin Pharmaceutical Co., Ltd manufactures and sells pharmaceutical products in South Korea. It offers various medicinal products, such as plaster, aerosol, topical liquid, emollient, hygiene, and ointment products, as well as adhesive bandages, mosquito repellents, anti-perspirants, cooling...

Key Financial Metrics

PriceKRW 4,315
Market Cap$51M
P/E (TTM)7.03
Price/Book0.87
Return on Equity18.3%
Return on Invested Capital17.6%
Debt/Equity0.51x
Gross Margin39.0%
Operating Margin12.0%
Revenue Growth14.9%
Dividend Yield1.9%
Free Cash Flow$5M

Sinsin Pharmaceutical Co., Ltd operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (South Korea).

Frequently Asked Questions

What is Sinsin Pharmaceutical Co., Ltd’s (002800.KQ) StockRank?
MoatMap’s StockRank for Sinsin Pharmaceutical Co., Ltd (002800.KQ) is 96/100, with a Strong Buy signal. It is a composite of Quality (69), Value (86), and Momentum (49), each scored against its sector. The composite is then ranked across MoatMap’s universe of 24,000+ stocks.
Does Sinsin Pharmaceutical Co., Ltd have an economic moat?
Sinsin Pharmaceutical Co., Ltd (002800.KQ) has a Quality factor score of 69/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Sinsin Pharmaceutical Co., Ltd a buy, hold, or sell?
MoatMap’s current signal for Sinsin Pharmaceutical Co., Ltd (002800.KQ) is Strong Buy, based on a StockRank of 96/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Sinsin Pharmaceutical Co., Ltd in?
Sinsin Pharmaceutical Co., Ltd (002800.KQ) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (South Korea).